Claritin for OTC allergy relief
This article was originally published in The Tan Sheet
Executive Summary
Almost half (42%) of allergy-sufferers surveyed intend to purchase Schering-Plough's Claritin (loratadine) when it is available OTC, according to study by market research firm Ipsos PharmTrends. Results indicate Claritin "would displace all other OTC and Rx drugs as the preferred remedy," since current OTC category leader, Pfizer Consumer Healthcare's Benadryl, was used by about 32% of allergy sufferers interviewed. Ipsos predicts S-P's successful DTC brand awareness campaign will "carry into the OTC arena, placing incremental pressure" on competing drugs; firm found 91% of allergy sufferers have heard of Claritin. Survey involved random sample of 1,000 adults nationwide...
You may also be interested in...
Financing Quarterly Statistics, Q1 2024
During Q1, biopharmas brought in an aggregate $30.1bn in financing and device company fundraising totaled $2.8bn; while in vitro diagnostic firms and research tools players raised $724m.
Helping Organizations Deliver On KPIs And Giving Staff A Voice
ImproveWell has won awards for its software technology that allows health care staff at the sharp end of patient care to report on problems as they happen. The outcome is a real-time learning process that contributes to improved operational efficiencies for health systems, says In Vivo Rising Leader Lara Mott.
EU Experts Want One-Stop-Shop EU Governance That Mimics Best Of Other Jurisdictions
It may be blue sky thinking to surmise how a new EU medtech regulatory governance structure could evolve. But with change on the horizon, experts see exciting opportunities.